Showing results (591-600 of 651) with videos related to

Sort By:
Pageof 66
EMBO Molecular Medicine|December 22, 2025
Impaired Complex I dysregulates neural/glial precursors and corpus callosum development revealing postnatal defects in Leigh syndrome miceSahitya Ranjan Biswas, Porter L Tomsick, Colin Kelly, et al.
Journal of the American Chemical Society|April 21, 2022
Three Mutations Convert the Selectivity of a Protein Sensor from Nicotinic Agonists to S-Methadone for Use in Cells, Organelles, and BiofluidsAnand K Muthusamy, Charlene H Kim, Scott C Virgil, et al.
Neuroscience|November 15, 2011
Nicotinic cholinergic mechanisms causing elevated dopamine release and abnormal locomotor behaviorB N Cohen, E D W Mackey, S R Grady, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|March 13, 2025
Continuous Nicotine Monitors for Personal Nicotine Pharmacokinetics: A Receptor-Aware Research AgendaAaron L Nichols, Christopher B Marotta, Heather L Lukas, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Interactive computational and experimental approaches improve the sensitivity of periplasmic binding protein-based nicotine biosensors for measurements in biofluidsNandan Haloi, Shan Huang, Aaron L Nichols, et al.
American Journal of Human Genetics|May 1, 2012
Mutations in NSUN2 cause autosomal-recessive intellectual disabilityLia Abbasi-Moheb, Sara Mertel, Melanie Gonsior, et al.
Neuron|September 5, 2006
The prototoxin lynx1 acts on nicotinic acetylcholine receptors to balance neuronal activity and survival in vivoJulie M Miwa, Tanya R Stevens, Sarah L King, et al.
The Medical Journal of Australia|March 29, 2000
Enhanced measles surveillance during an interepidemic period in VictoriaS B Lambert, H A Kelly, R M Andrews, et al.
ACS Chemical Biology|July 31, 2018
α1-FANGs: Protein Ligands Selective for the α-Bungarotoxin Site of the α1-Nicotinic Acetylcholine ReceptorAaron L Nichols, Kaori Noridomi, Christopher R Hughes, et al.
JTO Clinical and Research Reports|February 24, 2025
Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)Rachel E Reingold, Rose Parisi, Guilherme Harada, et al.
Pageof 66